Cancer Clinical Trial
— EROGOfficial title:
Analysis of the Specific Onco-geriatric Multidisciplinary Team Meeting (RCP) at E.Herriot Hospital (Hospices Civils de Lyon)
Verified date | September 2019 |
Source | Hospices Civils de Lyon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In France, cancer incidence increases over the course of life and therefore it is considered
as an important pathology of the elderly. Cancers are the second leading cause of death for
patients over 70 years old.
In 2015, 233,343 new cases of cancer were estimated for patients of 65 years and over (60.9%
of estimated cancers of all ages), 42,547 new cases for older people over 85 years old (about
11% of all diagnosed cancer cases).
With the expected aging of the population in the coming years, the number of patients over
the age of 70 will continue to increase. Life expectancy will also increase (12 years for the
people above 75 years old and more than 8 years for the people above 80 years old).
The elderly are a heterogeneous population. Some people age well with few chronic diseases
and a preserved autonomy. Others have several pathologies, geriatric syndromes (malnutrition,
functional disorders, sensory deficits or psycho-cognitive diseases). Poly-medication is
therefore common with an increased risk of iatrogenic disease. All these factors, in addition
to social and economic conditions, determine the health status of the elderly. The presence
of comorbidities decreases life expectancy and may itself be a contraindication to treatment.
Patients in this age group are therefore particularly exposed to the risks of over- or
under-treatment.
The multidisciplinary team meeting (RCP) is widely used for decision making in oncology.
Various official texts govern it (Plan Cancer, HAS). However, the onco-geriatric decision is
usually only a complementary opinion after a RCP of a specific organ.
Since 2006, the E. Herriot Hospital's Multidisciplinary team meeting has been organized to
discuss cases of patients over 70 years old. The specificity is the association of a real
multidisciplinary geriatric oncology discussion. The latter between medical specialist :
geriatrician, oncologist, surgeon, radiotherapist, pharmacist, onco-geriatric nurse allows
the development of an appropriate individualized therapeutic project for the patient.
The onco-geriatric multidisciplinary team is implementing a descriptive study of the RCP for
the management of patients above 70 with cancer. The Regional Network of Oncology
Auvergne-Rhône-Alpes is a partner.
The main aim is to describe the feasibility of the assessment of the follow-up of
onco-geriatric recommendations 4 months after the onco-geriatric RCP of E. Herriot Hospital
concerning patients with or with suspicion of cancer.
The secondary aims are : 1/ To describe the process of RCP: participants, patient's
characteristics and conclusions with recommendations, 2/ To assess the implementation of
oncological and geriatric recommendations 4 months after RCP 3/ To assess the survival,
autonomy and quality of life of patients 4 months after RCP.
The hypothesis is that onco-geriatric RCP's recommendations improve the outcome for the
patient.
The purpose of this pilot study is to ensure that the assessment of the recommendations'
follow-up at 4 months is feasible.
Status | Completed |
Enrollment | 120 |
Est. completion date | July 30, 2019 |
Est. primary completion date | July 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 70 Years and older |
Eligibility |
Inclusion Criteria: - Patients over 70 years - with cancer or suspicion of cancer, - with a systematic collection of oncological and geriatric data in their medical record submitted to the onco-geriatric RCP of E. Herriot hospital. - Patients must be able to express their non-opposition to participate in this study or must be accompanied by a trustworthy person able to express his or her opposition. Exclusion Criteria: - None |
Country | Name | City | State |
---|---|---|---|
France | Médecine Gériatrique/équipe mobile de gériatrie - Hôpital Edouard Herriot | Lyon | |
France | Oncologie radiothérapie - Hôpital Privé Jean Mermoz Ramsay Général de Santé Lyon | Lyon |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients whose recommendations' follow-up at 4 months after RCP, has been feasible. | Phone call 4 months after RCP to assess if recommendations have been followed. | 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|